Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2014

Open Access 01-12-2014 | Original investigation

Low levels of 1,5-anhydro-D-glucitol are associated with vascular endothelial dysfunction in type 2 diabetes

Authors: Keiichi Torimoto, Yosuke Okada, Hiroko Mori, Yoshiya Tanaka

Published in: Cardiovascular Diabetology | Issue 1/2014

Login to get access

Abstract

Background

Vascular endothelial dysfunction is involved in macrovascular disease progression in type 2 diabetes mellitus (T2DM). We reported previously that blood glucose fluctuations, as evaluated by continuous glucose monitoring (CGM), correlate with vascular endothelial function, serving as a marker of vascular endothelial function. However, the use of CGM is limited, suggesting the need for another marker of vascular endothelial function. Here, we investigated the relationship between vascular endothelial dysfunction and blood levels of 1,5-anhydro-D-glucitol (1,5-AG), a marker of both postprandial hyperglycemia and fluctuations in blood glucose.

Methods

In 32 inpatients with T2DM and HbA1c less than 8.0%, the reactive hyperemia index (RHI), an index of vascular endothelial function, was determined by peripheral arterial tonometry. The relationships between RHI and 1,5-AG, blood glucose, lipid metabolism markers, and blood pressure, were examined.

Results

There was a strong correlation between 1,5-AG and natural logarithmic-scaled RHI (L_RHI) (r = 0.55; P = 0.001). However, there was no correlation between L_RHI and HbA1c, fasting blood glucose, IRI, LDL-C, HDL-C, TG, systolic blood pressure, or diastolic blood pressure. Multivariate analysis identified blood 1,5-AG levels to be the only significant and independent determinant of L_RHI.

Conclusions

In T2DM with HbA1c <8.0%, low 1,5-AG levels were associated with vascular endothelial dysfunction, suggesting it is a potentially useful marker for vascular endothelial dysfunction.

Trial registration

Literature
1.
go back to reference Ross R: Atherosclerosis-An inflammatory disease. N Engl J Med. 1999, 340: 115-126. 10.1056/NEJM199901143400207.CrossRefPubMed Ross R: Atherosclerosis-An inflammatory disease. N Engl J Med. 1999, 340: 115-126. 10.1056/NEJM199901143400207.CrossRefPubMed
2.
go back to reference Xu J, Zou MH: Molecular insights and therapeutic targets for diabetic endothelial dysfunction. Circulation. 2009, 120: 1266-1286. 10.1161/CIRCULATIONAHA.108.835223.PubMedCentralCrossRefPubMed Xu J, Zou MH: Molecular insights and therapeutic targets for diabetic endothelial dysfunction. Circulation. 2009, 120: 1266-1286. 10.1161/CIRCULATIONAHA.108.835223.PubMedCentralCrossRefPubMed
3.
go back to reference Ceriello A, Esposito K, Piconi L, Ihnat MA, Thorpe JE, Testa R, Boemi M, Giugliano D: Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes. 2008, 57: 1349-1354. 10.2337/db08-0063.CrossRefPubMed Ceriello A, Esposito K, Piconi L, Ihnat MA, Thorpe JE, Testa R, Boemi M, Giugliano D: Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes. 2008, 57: 1349-1354. 10.2337/db08-0063.CrossRefPubMed
4.
go back to reference Torimoto K, Okada Y, Mori H, Tanaka Y: Relationship between fluctuations in glucose levels measured by continuous glucose monitoring and vascular endothelial dysfunction in type 2 diabetes mellitus. Cardiovasc Diabetol. 2013, 12: 1-10.1186/1475-2840-12-1.PubMedCentralCrossRefPubMed Torimoto K, Okada Y, Mori H, Tanaka Y: Relationship between fluctuations in glucose levels measured by continuous glucose monitoring and vascular endothelial dysfunction in type 2 diabetes mellitus. Cardiovasc Diabetol. 2013, 12: 1-10.1186/1475-2840-12-1.PubMedCentralCrossRefPubMed
5.
go back to reference Yamanouchi T, Tachibana Y, Akanuma H, Minoda S, Shinohara T, Moromizato H, Miyashita H, Akaoka I: Origin and disposal of 1,5-anhydroglucitol, a major polyol in the human body. Am J Physiol. 1992, 263: E268-E273.PubMed Yamanouchi T, Tachibana Y, Akanuma H, Minoda S, Shinohara T, Moromizato H, Miyashita H, Akaoka I: Origin and disposal of 1,5-anhydroglucitol, a major polyol in the human body. Am J Physiol. 1992, 263: E268-E273.PubMed
6.
go back to reference Yamanouchi T, Akanuma Y: Serum 1,5-anhydroglucitol (1,5 AG): new clinical marker for glycemic control. Diabetes Res Clin Pract. 1994, 24: S261-S268.CrossRefPubMed Yamanouchi T, Akanuma Y: Serum 1,5-anhydroglucitol (1,5 AG): new clinical marker for glycemic control. Diabetes Res Clin Pract. 1994, 24: S261-S268.CrossRefPubMed
7.
go back to reference Watanabe M, Kokubo Y, Higashiyama A, Ono Y, Miyamoto Y, Okamura T: Serum 1,5-anhydro-D-glucitol levels predict first-ever cardiovascular disease: an 11-year population-based cohort study in Japan, the Suita study. Atherosclerosis. 2011, 216: 477-483. 10.1016/j.atherosclerosis.2011.02.033.CrossRefPubMed Watanabe M, Kokubo Y, Higashiyama A, Ono Y, Miyamoto Y, Okamura T: Serum 1,5-anhydro-D-glucitol levels predict first-ever cardiovascular disease: an 11-year population-based cohort study in Japan, the Suita study. Atherosclerosis. 2011, 216: 477-483. 10.1016/j.atherosclerosis.2011.02.033.CrossRefPubMed
8.
go back to reference Kuvin JT, Patel AR, Sliney KA, Pandian NG, Sheffy J, Schnall RP, Karas RH, Udelson JE: Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude. Am Heart J. 2003, 146: 168-174. 10.1016/S0002-8703(03)00094-2.CrossRefPubMed Kuvin JT, Patel AR, Sliney KA, Pandian NG, Sheffy J, Schnall RP, Karas RH, Udelson JE: Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude. Am Heart J. 2003, 146: 168-174. 10.1016/S0002-8703(03)00094-2.CrossRefPubMed
9.
go back to reference Celermajer DS: Reliable endothelial function testing: at our fingertips?. Circulation. 2008, 117: 2428-2430. 10.1161/CIRCULATIONAHA.108.775155.CrossRefPubMed Celermajer DS: Reliable endothelial function testing: at our fingertips?. Circulation. 2008, 117: 2428-2430. 10.1161/CIRCULATIONAHA.108.775155.CrossRefPubMed
10.
go back to reference Flammer AJ1, Anderson T, Celermajer DS, Creager MA, Deanfield J, Ganz P, Hamburg NM, Lüscher TF: The assessment of endothelial function: from research into clinical practice. Circulation. 2012, 126: 753-767. 10.1161/CIRCULATIONAHA.112.093245.PubMedCentralCrossRefPubMed Flammer AJ1, Anderson T, Celermajer DS, Creager MA, Deanfield J, Ganz P, Hamburg NM, Lüscher TF: The assessment of endothelial function: from research into clinical practice. Circulation. 2012, 126: 753-767. 10.1161/CIRCULATIONAHA.112.093245.PubMedCentralCrossRefPubMed
11.
go back to reference Bonetti PO, Pumper GM, Higano ST, Holmes DR, Kuvin JT, Lerman A: Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol. 2004, 44: 2137-2141. 10.1016/j.jacc.2004.08.062.CrossRefPubMed Bonetti PO, Pumper GM, Higano ST, Holmes DR, Kuvin JT, Lerman A: Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol. 2004, 44: 2137-2141. 10.1016/j.jacc.2004.08.062.CrossRefPubMed
12.
go back to reference The Committee of Japan Diabetes Society on the diagnostic criteria of diabetes mellitus: Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Investig. 2010, 1: 212-228.CrossRef The Committee of Japan Diabetes Society on the diagnostic criteria of diabetes mellitus: Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Investig. 2010, 1: 212-228.CrossRef
13.
go back to reference Rubinshtein R, Kuvin JT, Soffler M, Lennon RJ, Lavi S, Nelson RE, Pumper GM, Lerman LO, Lerman A: Assessment of endothelial function by noninvasive peripheral arterial tonometry predicts late cardiovascular adverse events. Eur Heart J. 2010, 31: 1142-1148. 10.1093/eurheartj/ehq010.CrossRefPubMed Rubinshtein R, Kuvin JT, Soffler M, Lennon RJ, Lavi S, Nelson RE, Pumper GM, Lerman LO, Lerman A: Assessment of endothelial function by noninvasive peripheral arterial tonometry predicts late cardiovascular adverse events. Eur Heart J. 2010, 31: 1142-1148. 10.1093/eurheartj/ehq010.CrossRefPubMed
14.
go back to reference Mehta SN, Schwartz N, Wood JR, Svoren BM, Laffel LM: Evaluation of 1,5-anhydroglucitol, hemoglobin A1c, and glucose levels in youth and young adults with type 1 diabetes and healthy controls. Pediatr Diabetes. 2012, 13: 278-284. 10.1111/j.1399-5448.2011.00830.x.PubMedCentralCrossRefPubMed Mehta SN, Schwartz N, Wood JR, Svoren BM, Laffel LM: Evaluation of 1,5-anhydroglucitol, hemoglobin A1c, and glucose levels in youth and young adults with type 1 diabetes and healthy controls. Pediatr Diabetes. 2012, 13: 278-284. 10.1111/j.1399-5448.2011.00830.x.PubMedCentralCrossRefPubMed
15.
go back to reference Dungan KM: 1,5-anhydroglucitol (GlycoMark) as a marker of short-term glycemic control and glycemic excursions. Expert Rev Mol Diagn. 2008, 8: 9-19. 10.1586/14737159.8.1.9.CrossRefPubMed Dungan KM: 1,5-anhydroglucitol (GlycoMark) as a marker of short-term glycemic control and glycemic excursions. Expert Rev Mol Diagn. 2008, 8: 9-19. 10.1586/14737159.8.1.9.CrossRefPubMed
16.
go back to reference Sun J, Dou JT, Wang XL, Yang GQ, Lü ZH, Zheng H, Ma FL, Lu JM, Mu YM: Correlation between 1,5-anhydroglucitol and glycemic excursions in type 2 diabetic patients. Chin Med J (Engl). 2011, 124: 3641-3645. Sun J, Dou JT, Wang XL, Yang GQ, Lü ZH, Zheng H, Ma FL, Lu JM, Mu YM: Correlation between 1,5-anhydroglucitol and glycemic excursions in type 2 diabetic patients. Chin Med J (Engl). 2011, 124: 3641-3645.
17.
go back to reference Sakamoto M1, Nishimura R, Irako T, Tsujino D, Ando K, Utsunomiya K: Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study). Cardiovasc Diabetol. 2012, 11: 92-10.1186/1475-2840-11-92.PubMedCentralCrossRefPubMed Sakamoto M1, Nishimura R, Irako T, Tsujino D, Ando K, Utsunomiya K: Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study). Cardiovasc Diabetol. 2012, 11: 92-10.1186/1475-2840-11-92.PubMedCentralCrossRefPubMed
18.
go back to reference Fujiwara T1, Yoshida M, Yamada H, Tsukui T, Nakamura T, Sakakura K, Wada H, Arao K: Lower 1,5-anhydroglucitol is associated with denovo coronary artery disease in patients at high cardiovascular risk. Heart Vessels. 2014, Apr 2: [Epub ahead of print] Fujiwara T1, Yoshida M, Yamada H, Tsukui T, Nakamura T, Sakakura K, Wada H, Arao K: Lower 1,5-anhydroglucitol is associated with denovo coronary artery disease in patients at high cardiovascular risk. Heart Vessels. 2014, Apr 2: [Epub ahead of print]
19.
go back to reference Yamanouchi T, Akaoka I, Akanuma Y, Akanuma H, Miyashita E: Mechanism for acute reduction of 1,5-anhydroglucitol in rats treated with diabetogenic agents. Am J Physiol. 1990, 258: E423-E427.PubMed Yamanouchi T, Akaoka I, Akanuma Y, Akanuma H, Miyashita E: Mechanism for acute reduction of 1,5-anhydroglucitol in rats treated with diabetogenic agents. Am J Physiol. 1990, 258: E423-E427.PubMed
20.
go back to reference Yamanouchi T, Moromizato H, Shinohara T, Minoda S, Miyashita H, Akaoka I: Estimation of plasma glucose fluctuation with a combination test of hemoglobin A1c and 1,5-anhydroglucitol. Metabolism. 1992, 41: 862-867. 10.1016/0026-0495(92)90168-A.CrossRefPubMed Yamanouchi T, Moromizato H, Shinohara T, Minoda S, Miyashita H, Akaoka I: Estimation of plasma glucose fluctuation with a combination test of hemoglobin A1c and 1,5-anhydroglucitol. Metabolism. 1992, 41: 862-867. 10.1016/0026-0495(92)90168-A.CrossRefPubMed
21.
go back to reference Yamanouchi T, Ogata N, Tagaya T, Kawasaki T, Sekino N, Funato H, Akaoka L, Miyashita H: Clinical usefulness of serum 1,5-anhydroglucitol in monitoring glycaemic control. Lancet. 1996, 347: 1514-1518. 10.1016/S0140-6736(96)90672-8.CrossRefPubMed Yamanouchi T, Ogata N, Tagaya T, Kawasaki T, Sekino N, Funato H, Akaoka L, Miyashita H: Clinical usefulness of serum 1,5-anhydroglucitol in monitoring glycaemic control. Lancet. 1996, 347: 1514-1518. 10.1016/S0140-6736(96)90672-8.CrossRefPubMed
22.
go back to reference Kishimoto M, Yamasaki Y, Kubota M, Arai K, Morishima T, Kawamori R, Kamada T: 1,5-Anhydro-D-glucitol evaluates daily glycemic excursions in well-controlled NIDDM. Diabetes Care. 1995, 18: 1156-1159. 10.2337/diacare.18.8.1156.CrossRefPubMed Kishimoto M, Yamasaki Y, Kubota M, Arai K, Morishima T, Kawamori R, Kamada T: 1,5-Anhydro-D-glucitol evaluates daily glycemic excursions in well-controlled NIDDM. Diabetes Care. 1995, 18: 1156-1159. 10.2337/diacare.18.8.1156.CrossRefPubMed
23.
go back to reference Yamanouchi T, Kawasaki T, Yoshimura T, Inoue T, Koshibu E, Ogata N, Funato H, Akaoka I, Miyashita H: Relationship between serum 1,5-anhydroglucitol and urinary excretion of N-acetylglucosaminidase and albumin determined at onset of NIDDM with 3-year follow-up. Diabetes Care. 1998, 21: 619-624. 10.2337/diacare.21.4.619.CrossRefPubMed Yamanouchi T, Kawasaki T, Yoshimura T, Inoue T, Koshibu E, Ogata N, Funato H, Akaoka I, Miyashita H: Relationship between serum 1,5-anhydroglucitol and urinary excretion of N-acetylglucosaminidase and albumin determined at onset of NIDDM with 3-year follow-up. Diabetes Care. 1998, 21: 619-624. 10.2337/diacare.21.4.619.CrossRefPubMed
24.
go back to reference Ohira M, Endo K, Oyama T, Yamaguchi T, Ban N, Kawana H, Nagayama D, Nagumo A, Saiki A, Murano T, Watanabe H, Miyashita Y, Shirai K: Improvement of postprandial hyperglycemia and arterial stiffness upon switching from premixed human insulin 30/70 to biphasic insulin aspart 30/70. Metabolism. 2011, 60: 78-85. 10.1016/j.metabol.2010.06.001.CrossRefPubMed Ohira M, Endo K, Oyama T, Yamaguchi T, Ban N, Kawana H, Nagayama D, Nagumo A, Saiki A, Murano T, Watanabe H, Miyashita Y, Shirai K: Improvement of postprandial hyperglycemia and arterial stiffness upon switching from premixed human insulin 30/70 to biphasic insulin aspart 30/70. Metabolism. 2011, 60: 78-85. 10.1016/j.metabol.2010.06.001.CrossRefPubMed
25.
go back to reference Emoto T, Sawada T, Hashimoto M, Kageyama H, Terashita D, Mizoguchi T, Mizuguchi T, Motodi Y, Iwasaki M, Taira K, Okamoto H, Matsuo Y, Kim SK, Takarada A, Yokoyama M: Effect of 3-month repeated administration of miglitol on vascular endothelial function in patients with diabetes mellitus and coronary artery disease. Am J Cardiol. 2012, 109: 42-46. 10.1016/j.amjcard.2011.08.005.CrossRefPubMed Emoto T, Sawada T, Hashimoto M, Kageyama H, Terashita D, Mizoguchi T, Mizuguchi T, Motodi Y, Iwasaki M, Taira K, Okamoto H, Matsuo Y, Kim SK, Takarada A, Yokoyama M: Effect of 3-month repeated administration of miglitol on vascular endothelial function in patients with diabetes mellitus and coronary artery disease. Am J Cardiol. 2012, 109: 42-46. 10.1016/j.amjcard.2011.08.005.CrossRefPubMed
26.
go back to reference Nohria A, Gerhard-Herman M, Creager MA, Hurley S, Mitra D, Ganz P: Role of nitric oxide in the regulation of digital pulse volume amplitude in humans. J Appl Physiol. 2006, 101: 545-548. 10.1152/japplphysiol.01285.2005.CrossRefPubMed Nohria A, Gerhard-Herman M, Creager MA, Hurley S, Mitra D, Ganz P: Role of nitric oxide in the regulation of digital pulse volume amplitude in humans. J Appl Physiol. 2006, 101: 545-548. 10.1152/japplphysiol.01285.2005.CrossRefPubMed
27.
go back to reference Dungan KM, Buse JB, Largay J, Kelly MM, Button EA, Kato S, Wittlin S: 1,5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care. 2006, 29: 1214-1219. 10.2337/dc06-1910.CrossRefPubMed Dungan KM, Buse JB, Largay J, Kelly MM, Button EA, Kato S, Wittlin S: 1,5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care. 2006, 29: 1214-1219. 10.2337/dc06-1910.CrossRefPubMed
28.
go back to reference Hamburg NM, Keyes MJ, Larson MG, Vasan RS, Schnabel R, Pryde MM, Mitchell GF, Sheffy J, Vita JA, Benjamin EJ: Cross-sectional relations of digital vascular function to cardiovascular risk factors in the Framingham Heart Study. Circulation. 2008, 117: 2467-2474. 10.1161/CIRCULATIONAHA.107.748574.PubMedCentralCrossRefPubMed Hamburg NM, Keyes MJ, Larson MG, Vasan RS, Schnabel R, Pryde MM, Mitchell GF, Sheffy J, Vita JA, Benjamin EJ: Cross-sectional relations of digital vascular function to cardiovascular risk factors in the Framingham Heart Study. Circulation. 2008, 117: 2467-2474. 10.1161/CIRCULATIONAHA.107.748574.PubMedCentralCrossRefPubMed
Metadata
Title
Low levels of 1,5-anhydro-D-glucitol are associated with vascular endothelial dysfunction in type 2 diabetes
Authors
Keiichi Torimoto
Yosuke Okada
Hiroko Mori
Yoshiya Tanaka
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2014
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/1475-2840-13-99

Other articles of this Issue 1/2014

Cardiovascular Diabetology 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.